IMMUNIC, INC.
IMUX · XNASCIK 1280776fmd_054F1X035ARKN1MB3FHW91MQ8KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Property operating expenses | 1 | 1 | – | – | – | – | – | – | – | – |
| Provision for credit losses | – | – | – | – | – | – | – | – | 0 | 0 |
| Research and development | 30 | 39 | 10 | 23 | 39 | 61 | 71 | 83 | 80 | 82 |
| Total operating expenses | 41 | 53 | 12 | 37 | 49 | 92 | 119 | 99 | 98 | 103 |
| Operating income | (41) | (53) | (12) | (37) | (49) | (92) | (119) | (99) | (98) | (103) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 | 3 | 1 |
| Other non-operating income (expense) | 0 | 1 | 0 | 2 | 5 | (1) | (1) | 6 | (2) | 6 |
| Income before taxes | (41) | (52) | (41) | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | – | – | – | 0 |
| Net income | (41) | (52) | (12) | (35) | (44) | (93) | (120) | (94) | (101) | (97) |
| Net income to common shareholders | (41) | (52) | – | – | – | – | – | – | – | – |